camp-20250611

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2025

CAMP4 THERAPEUTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-42365

81-1152476

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

One Kendall Square

Building 1400 West, 3rd Floor

Cambridge, MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 651-8867

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share

CAMP

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 11, 2025, CAMP4 Therapeutics Corporation (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 30, 2025.

1.The following nominees were elected as the Company’s Class I directors, each to serve for a three-year term until the 2028 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes:


Nominees	For	Against	Abstain	Broker Non-Votes
James Boylan	15,802,709	900,961	6,002	1,199,173
Amir Nashat, ScD	16,050,167	653,504	6,001	1,199,173
Andrew J. Schwab	16,050,167	653,504	6,001	1,199,173
Douglas Williams, PhD	16,700,927	2,744	6,001	1,199,173

2.The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2025 was ratified, based on the following votes:


For	Against	Abstain
17,900,199	2,644	6,002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			CAMP4 THERAPEUTICS CORPORATION

			By:			/s/ Kelly Gold
						Name: Kelly Gold
						Title: Chief Financial Officer

Date: June 13, 2025

CAMP4 Therapeutics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders